AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04366180 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group will received one placebo capsule per day during 2 months
Study NCT03546829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: 125 mg, 4x daily for 5 weeks
Study NCT03546829 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Precision hypofractionated radiation
Description: Patients planned to undergo precision hypofractionated radiation to all sites of oligoprogression and will receive vancomycin for 1 week before RT and for 1 month after start of RT, and asked to provide stool and blood samples as outlined in the Safety Trial study table.
Study NCT03336879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation technique. The investigators will use a MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
Study NCT02690935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2LALERG
Description: Homeopathic drug
Study NCT02690935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01740791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velpatasvir
Description: Tablets administered orally
Study NCT01740791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally
Study NCT02777983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video App
Description: The content of the app will be grounded in a biopsychosocial model and modeled on the Back Book, a booklet developed to help modify beliefs and behavior of patients with LBP. Essentially this will take the primary concepts and ideas often given in print or verbal form, and present it in a more engaging and dynamic fashion.
Study NCT03468920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
Study NCT00585390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA fish oil concentrate; DHA fish oil concentrate
Description: 3.2 grams for EPA 1.6 grams for DHA
Study NCT00585390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive oil capsule
Study NCT01475409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QuantiFERON-TB Gold In-Tube (QFT-GIT)
Description: Patients were randomized to undergo, on the same day, TST and QFT-GIT by means of a randomization list to generate the order by which the 2 tests had to be executed. QFT-GIT was repeated after 3 and 6 months since TNF antagonist onset
Study NCT00503516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Description: 1 sachet of powder containing 160 mg of megestrol acetate b.i.d. during 24 weeks
Study NCT00503516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet of 160 mg of placebo b.i.d.
Study NCT03810144 — intervention group
Intervention type: GENETIC
Intervention: Vectra MBDA Test
Description: Vectra Guided versus Usual Care
Study NCT04307784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VD3
Description: VD3 (50.000 IU/week) for 8 weeks
Study NCT04307784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3FA
Description: Omaga-3FA (300 mg/day) for 8 weeks
Study NCT04307784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VD3 and Omega-3FA
Description: VD3 (50.000 IU/week) and (Omega-3FA 300 mg /day) for 8 weeks
Study NCT04307784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No intervention is given
Study NCT02460445 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: Scheduled standard phlebotomy every three months from month 3 to 12 of follow-up.
Study NCT02460445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethinylestradiol
Description: 35 mcg ethinylestradiol qd for 21 days per month as usual clinical practice.
Study NCT03396861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Subconjunctival aflibercept
Study NCT06642714 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: weaning by early non-invasive ventilation and progressive high flow oxygen therapy
Description: Step 1 Clinical stability was confirmed:~(1)Without organ failure;(2)Without sepsis;(3)Stable heart rate and blood pressure without use of vascular active drugs.~Step2 Reduce the support parameters of the ventilator gradually. Step3 SBT when the ventilator mode is pressure support ventilation(PSV),P+PEEP≤16cmH2O for 2 hours.~Step4~①Success of SBT: titrate based HFOT time-------connected with tracheostomy tube ,flow rate and FiO2 able to maintain oxygen saturation as assessed by pulse oximetry monitoring of at least 95%.HFOT was interrupted in cases of sighs or symptoms of distress such as oxygen desaturation, RR>30bpm, HR>130bpm,SBP>180mmHg or \<90mmHg.The time was based HFOT time. When any of these conditions were present the patient was connected again to the ventilator with the same parameters before titration. The duration of SBT was increased progressively over the following day according to patient tolerance. Then gradually extending HFOT time daily according patient condition. Wh
Study NCT02460445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethinylestradiol
Description: 35 mcg ethinylestradiol qd for 21 days per month as usual clinical practice.
Study NCT02460445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyproterone Acetate
Description: 2 mg cyproterone acetate qd for 21 days per month as usual clinical practice.
Study NCT02460445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproterone Acetate
Description: 2 mg cyproterone acetate qd for 21 days per month as usual clinical practice.
Study NCT03468920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PO Acetaminophen
Description: Acetaminophen PO 1000mg once pre-operatively
Study NCT03094403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic Acid 15% topical gel
Description: Gel
Study NCT03468920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PO Placebo
Description: PO placebo capsule compounded to match PO Acetaminophen capsule
Study NCT03468920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Solution Placebo
Description: This will serve as the placebo for the IV Acetaminophen intervention
Study NCT03873324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL500036 compound
Description: IMP is a capsule with CPL500036 as an Active Pharmaceutical Ingredient (API).
Study NCT05418426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVR Dose 1
Description: Estradiol 80 ug/progesterone 4 mg
Study NCT05418426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVR Dose 2
Description: Estradiol 160ug/progesterone 8 mg
Study NCT05418426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Reference
Description: estradiol 1mg/progesterone 100 mg
Study NCT01851798 — intervention group
Intervention type: OTHER
Intervention: Home sleep test administered to all enrolled subjects
Study NCT01066299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon®
Description: single dose of OXT (24 IU)
Study NCT01066299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: inactive nasal spray
Description: single dose (24 IU)
Study NCT03329131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: An Elasto gel™ frozen (4°C) glove and sock
Study NCT02228330 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: obturator nerve block
Description: a uni-lateral obturator nerve block will be performed under ultrasound guidance- using 2% lidocaine for obtaining a short term block.
Study NCT04103814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium-cannabidiolic acid cream
Description: Patients will receive Mg-CBDa (magnesium-cannabidiolic acid) cream for topical treatment of hallux rigidus or hallux valgus.
Study NCT04103814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Patients will receive placebo cream (neutral emollient containing no active agent) for topical treatment of hallux rigidus or hallux valgus. The ingredients of the placebo cream are as follows: Butyrospermum parkii (shea butter), caprylic/capric triglycerides medium-chain triglycerides (MCT oil), food coloring to match the CBD oil. There will be 345 grams of shea butter and 62ml MCT oil per batch.
Study NCT01657331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Dose escalation in phase I of the study from 1.2-1.8 mg/kg, IV infusions over 30 minutes on day 1 of each 21-day cycle.
Study NCT01657331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Dose escalation in phase I of the study from 60-100 mg/m2, IV infusion on days 1 and 2 of each 21-day cycle.
Study NCT03873324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsules
Study NCT04467463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral nerve block by 0.25% levobupivacaine
Description: SUBMANDIBULAR nerve block will be performed using a 25G 90 mm beveled needle . the entry point of the needle will be situated at the angle formed by the superior edge of the zygomatic arch below and the posterior orbital rim forward .The needle will be inserted perpendicular to the skin and advanced approximately 20 mm depth to reach the greater wing of the sphenoid deep to the pterygopalatine fossa. Injection of 1ml of 0.25% levobupivacaine will be done over 20 seconds afterensuring negative blood aspiration .greater Palatine Nerve will be blocked bilaterally as it leaves on palatal side through the foramen on the opposite direction of the anterior part of the 3rd molar orthe posterior part of the 2nd molar tooth.
Study NCT02908620 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: One spray CTY-5339-A
Description: Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.
Study NCT02908620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One spray CTY-5339-CB
Description: Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
Study NCT02908620 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Two sprays CTY-5339-A
Description: Metered spray bottle with ≈400 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 56 mg total) and 2.0% Tetracaine Hydrochloride (USP = 8 mg total). Administered in two anesthetic sprays.
Study NCT02908620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo)
Description: A single spray of CTY-5339-CB in a metered spray bottle with ≈200 uL total spray volume, containing the active ingredient: 14.0% Benzocaine (USP = 28 mg). This was administered in combination with a single spray of CTY-5339-P (acting as vehicle control placebo with no active ingredient) in a metered spray bottle with ≈200 uL total spray volume. This combination was used to maintain double-blind conditions. The vehicle control was sprayed outside the circumscribed area to avoid dilution of active drug.
Study NCT02292394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Cognitive Behavioral Telephone Intervention
Study NCT02292394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Intervention Pleasant Activities
Study NCT01657331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta
Description: (Non-experimental) Standard procedure prophylactic pegfilgrastim on day 3 of any subsequent cycle after cycle 1, or filgrastim for 5 to 10 days, per investigator's discretion.
Study NCT05938569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hair restoration
Description: The Study Treatment will involve follicular hair unit harvest, recipient site making, and implantation.
Study NCT02868931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INPUT
Description: Treatment and education program based on the self-management theory of behavioral medicine.~The program is delivered by certified and specially trained diabetes educators.
Study NCT02315976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propatyl Nitrate
Description: Propatyl nitrate 10mg administered orally, three times daily
Study NCT00844428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eculizumab
Description: All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
Study NCT04871633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Remdesivir is an intravenous (IV) loading dose of 200 mg on day 1 followed by daily IV maintenance doses of 100 mg for 5-10 days
Study NCT04871633 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Conventional
Description: IV Steroids Antibiotics
Study NCT04342546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovaGray RILA Breast® test
Description: The test consists of a blood sample of 2x4 mL. This test will be performed between day -30 and until the first day of radiotherapy (before the start of this one) and then 12 months after the end of radiotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of neoadjuvant chemotherapy and between day -30 and until the first day of chemotherapy (before any injection) in the case of adjuvant chemotherapy.
Study NCT00192478 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Medi-524
Description: IM doses of MEDI-524 administered at 3 mg/kg or 15 mg/kg at 30 day intervals
Study NCT01254929 — intervention group
Intervention type: DEVICE
Intervention: F-18 PET bone scan
Description: Following the intravenous administration of approximately 10 mCi F-18, subjects will undergo an F-18 PET bone scan.
Study NCT01254929 — intervention group
Intervention type: DEVICE
Intervention: Tc-99m bone scan
Description: Following the intravenous administration of approximately 30mCi Tc-99m MDP, subjects will undergo a traditional bone scan on a gamma camera.
Study NCT03094403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finacea® (azelaic acid) Gel, 15%
Description: Gel
Study NCT04871633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: IV Steroids Antibiotics
Study NCT00788658 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diet modifications
Description: Diet consultation
Study NCT03094403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gel
Study NCT02983565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent oxygen therapy system (iO2Ts)
Study NCT04423783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7-day exposure therapy via self-developed app according to (Haberkamp et al., submitted)
Description: Confrontation with spiders via gamified app
Study NCT02034565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study NCT00581919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bort, Dex, and Dox with ALCAR
Description: Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 Dexamethasone 20 mg PO days 1, 4, 8, and 11 Doxorubicin 15 mg/m2 IV days 1 and 8 Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21 Maximum of 8 cycles. Each cycle is 21 days long
Study NCT03277872 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscopy with GlideScope (GVL) Blade
Description: 1. st Laryngoscopy with GVL Blade~2. nd Laryngoscopy with MAC Blade~3. rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization
Study NCT03293667 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exploratory synovial fluid analysis
Description: An additional blood sample (3 10 ml tubes) and an additional specific analysis to characterize subpopulations of regulating T lymphocytes infiltrating the synovium of RA patients and comparing them with those of peripheral blood.
Study NCT03277872 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscopy with MacIntosh (MAC) Blade
Description: 1. st Laryngoscopy with MAC Blade~2. nd Laryngoscopy with GVL Blade~3. rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization
Study NCT04090606 — intervention group
Intervention type: OTHER
Intervention: FTC Method Smoking Regimen
Description: cigarettes are smoked by drawing 35 mL puff volumes over 2 s, with 60 s interval between puffs and no blocking of filter ventilation holes
Study NCT04090606 — intervention group
Intervention type: OTHER
Intervention: Massachusetts Method Smoking Regimen
Description: 45-mL puffs drawn over 2 s, with 30 s interval between puffs and 50% blocking of filter ventilation holes
Study NCT04090606 — intervention group
Intervention type: OTHER
Intervention: Health Canada Intense Smoking Regimen
Description: 55-mL puff volumes of 2-s duration, with 30 s interval between puffs and 100% blocking of filter ventilation holes
Study NCT04423783 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist-guided one-session online exposure therapy according to (Öst, 1989)
Description: Massed exposure therapy over the course of one single session, applied in a remote-online context
Study NCT04423783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-guided one-session online exposure therapy according to (Öst, 1989)
Description: Massed exposure therapy over the course of one single session, applied in a remote-online context
Study NCT00788658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: Cognitive behavioral therapy
Study NCT01791868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Sodium Valproate
Description: According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
Study NCT00881335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flutter mucus clearance device
Description: five minutes every sessions, three sessions per day
Study NCT01963026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ToCUEST featuring a 'variable practice' approach.
Description: Intervention Variable practice: The ToCUEST (Task-Oriented Client-centred Upper Extremity Skill Training) module \[17\] will be given to the participants, in which individual goals will be extracted using the COPM (Canadian Occupational Performance Measure). The training program will start with a task analysis and is based on principles of training physiology and motor learning, including variability practice, random practice, distribution based practice, feedback, whole learning. A detailed description of the ToCUEST module is given in Spooren et al. \[17\]. Intervention B will be called 'ToCUEST variability' in the present project.
Study NCT01963026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ToCUEST featuring a 'constant practice' approach.
Description: Intervention Constant practice: In order to evaluate the contribution of the component 'variability practice' in contrast with 'constant practice' the participants will be offered the modified ToCUEST ('ToCUEST constant') module in which the component 'variability practice' is replaced by 'constant practice'.
Study NCT01521585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 50 mg oral once daily tablet
Study NCT01521585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEN0014196
Description: 200 mg oral once daily tablet
Study NCT01521585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral once daily tablet
Study NCT01403792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: P2G12
Description: A single intravaginal administration of 1ml P2G12/placebo.
Study NCT01403792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2G12
Description: A single intravaginal administration of 1ml P2G12/placebo.
Study NCT02094794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT02094794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT02094794 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total marrow irradiation
Description: Undergo TMLI
Study NCT00820508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHR-2845
Description: Once daily oral ingestion of capsules (10, 40 or 80mg), dose depending on cohort, treatment cycle of 28 days